CRISPR THERAPEUTICS AG
|
(Name of Issuer)
|
Common Shares, par value CHF 0.03 per share
|
(Title of Class of Securities)
|
H17182108
|
(CUSIP Number)
|
Ian F. Smith
Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston, Massachusetts 02210
(617) 341-6100
|
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
|
December 20, 2018
|
(Date of Event which Requires Filing of this Statement)
|
CUSIP No. H17182108
|
13D
|
Page 2 of 7 Pages
|
1.
|
NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Vertex Pharmaceuticals Incorporated (“Vertex US”)
|
2.
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a) ☐
(b) ☐ |
3.
|
SEC USE ONLY
|
4.
|
SOURCE OF FUNDS (see instructions)
WC
|
5.
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ☐
|
6.
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Massachusetts
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
7.
|
SOLE VOTING POWER
0
|
8.
|
SHARED VOTING POWER
|
|
9.
|
SOLE DISPOSITIVE POWER
0
|
|
10.
|
SHARED DISPOSITIVE POWER
|
11.
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
12.
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(see instructions) ☐
|
13.
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
|
14.
|
TYPE OF REPORTING PERSON (see instructions)
CO
|
CUSIP No. H17182108
|
13D
|
Page 3 of 7 Pages
|
1.
|
NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Vertex Pharmaceuticals (Europe) Limited (“Vertex Europe”)
|
2.
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions) (a) ☐
(b) ☐
|
3.
|
SEC USE ONLY
|
4.
|
SOURCE OF FUNDS (see instructions)
WC
|
5.
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ☐
|
6.
|
CITIZENSHIP OR PLACE OF ORGANIZATION
England and Wales
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
7.
|
SOLE VOTING POWER
0
|
8.
|
SHARED VOTING POWER
5,250,000
|
|
9.
|
SOLE DISPOSITIVE POWER
0
|
|
10.
|
SHARED DISPOSITIVE POWER
|
11.
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
5,250,000
|
12.
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(see instructions) ☐
|
13.
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
10.1% (1)
|
14.
|
TYPE OF REPORTING PERSON (see instructions)
OO
|
CUSIP No. H17182108
|
13D
|
Page 4 of 7 Pages
|
CUSIP No. H17182108
|
13D
|
Page 5 of 7 Pages
|
CUSIP No. H17182108
|
13D
|
Page 6 of 7 Pages
|
Exhibit 1 |
Joint Filing Agreement.
|
Exhibit 2 |
Strategic Collaboration, Option and License Agreement, dated October 26, 2015, by and between, on the one hand, Vertex Pharmaceuticals Incorporated and Vertex
Pharmaceuticals (Europe) Limited, and on the other hand, CRISPR Therapeutics AG, CRISPR Therapeutics, Inc., CRISPR Therapeutics Limited and TRACR Hematology Ltd. (incorporated herein by reference to Exhibit 10.4 to the Company’s
Registration Statement on Form S-1 filed on October 7, 2016).
|
Exhibit 3 |
Amendment No. 1 to the Strategic Collaboration, Option and License Agreement by and between, on the one hand, Vertex Pharmaceuticals Incorporated and Vertex
Pharmaceuticals (Europe) Limited, and on the other hand, CRISPR Therapeutics AG, CRISPR Therapeutics, Inc., CRISPR Therapeutics Limited and TRACR Hematology Ltd., dated as of December 12, 2017 (incorporated herein by reference to
Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on December 18, 2017).
|
CUSIP No. H17182108
|
13D
|
Page 7 of 7 Pages
|
VERTEX PHARMACEUTICALS INCORPORATED
|
||
By:
|
/s/ Ian F. Smith
|
|
Ian F. Smith
|
||
EVP, Chief Operating Officer and interim Chief Financial Officer
|
||
December 21, 2018
|
||
VERTEX PHARMACEUTICALS (EUROPE) LIMITED
|
||
By:
|
/s/ Ian F. Smith
|
|
Ian F. Smith
|
||
Director
|
||
December 21, 2018
|
Name
|
Present Principal Occupation or Employment
|
|
Jeffrey M. Leiden
|
Director of Vertex
Chairman, Chief Executive Officer and President of Vertex
Director of Quest Diagnostics Inc.
Director Massachusetts Mutual Life Insurance Company
|
|
Sangeeta N. Bhatia
|
Director of Vertex
John J. and Dorothy Wilson Professor of
Health Sciences & Technology/Electrical Engineering & Computer Science at the Massachusetts Institute of Technology
|
|
Bruce I. Sachs
|
Director of Vertex
General Partner at Charles River Ventures
|
|
Terrence C. Kearney
|
Director of Vertex
Director of Acceleron Pharma Inc.
|
|
Yuchun Lee
|
Director of Vertex
Executive in Residence and Partner of General Catalyst Partners
Chief Executive Officer of Allego Inc.
Executive Chairman of Clarabridge
|
|
Elaine S. Ullian
|
Director of Vertex
Director of Thermo Fisher Scientific Inc.
|
|
Margaret G. McGlynn
|
Director of Vertex
Director of Air Products and Chemicals, Inc.
Director of Amicus Therapeutics, Inc.
Member of the National Industrial Advisory Committee at the University at Buffalo School of Pharmacy and Pharmaceutical Sciences
|
|
William D. Young
|
Director of Vertex
Venture Partner at Clarus Ventures
Chairman of the Board of Directors of NanoString Technologies, Inc.
|
|
Alan Garber
|
Director of Vertex
Provost of Harvard University
Mallinckrodt Professor of Health Care Policy at Harvard Medical School
Professor of Economics in the Faculty of Arts and Sciences
Professor of Public Policy in the Harvard Kennedy School of Government
Professor in the Department of Health Policy and Management in the Harvard T.H. Chan School of Public Health
Fellow of the American Association for the Advancement of Science, the American College of Physicians, and the Royal College of Physicians
Research Associate with the National Bureau of Economic Research
|
|
David M. Altshuler
|
EVP, Global Research and Chief Scientific Officer of Vertex
|
|
Stuart Arbuckle
|
EVP, Chief Commercial Officer
|
|
Reshma Kewalramani
|
EVP, Global Medicines Development and Medical Affairs and Chief Medical Officer
|
|
Michael Parini
|
EVP, Chief Legal and Administrative Officer of Vertex
|
|
Amit Sachdev
|
EVP, Chief Regulatory Officer of Vertex
|
|
Ian F. Smith
|
EVP, Chief Operating Officer and interim Chief Financial Officer of Vertex
|
Name
|
Present Principal Occupation or Employment
|
|
Ian F. Smith
|
EVP, Chief Operating Officer and interim Chief Financial Officer of Vertex
|
|
Michele Bellandi
|
VP, International Commercial Management
|
|
Simon Lem
|
VP, Regional General Manager UK
|
VERTEX PHARMACEUTICALS INCORPORATED
|
||
By:
|
/s/ Ian F. Smith
|
|
Ian F. Smith
|
||
EVP, Chief Operating Officer and interim Chief Financial Officer
|
||
VERTEX PHARMACEUTICALS (EUROPE) LIMITED
|
||
By:
|
/s/ Ian F. Smith
|
|
Ian F. Smith
|
||
Director
|